Brochure | April 3, 2014

4•6•8 Promise™: Contract Pharma Development & Manufacturing

Source: Patheon Inc.

4 - Quick to Clinic™ solid dose molecules will be formulated and ready for distribution to phase 1 clinical trials in just four months from receipt of API.

6 - Quick to Market™ solid dose or liquid products will be transferred and ready for regulatory filing in just  six months from receipt of analytical methods and API. This enables clients to move products very quickly out of their plants and facilitate rationalization programs.

8 - Quick to Market™ aseptic liquid or lyophilized sterile products will be ready for regulatory filing in just  eight months from receipt of analytical methods and API.

For full access to this content, please Register or Sign In.

Access Content 4•6•8 Promise™: Contract Pharma Development & Manufacturing